Ranbaxy

News across the web »
Interact & exchange stock tips & market info »

imranbro

Silver Member

0 Follower

MMB Messenger

Platinum Member

112825 Followers

Related News »
MUMBAI (Reuters) - Ranbaxy Laboratories (RANB.NS) has received U.S. approval for acne treatment drug Absorica and expects a U.S. launch in the fourth quarter of this year. The product was jointly developed by Canadian group Cipher ...
May 28, 2012 at 11:06 | Source: Reuters India
Sudarshan Sukhani, s2analytics.com feels that one can buy Ranbaxy Laboratories and avoid OMCs stocks. Sukhani told CNBC-TV18, “ Ranbaxy Laboratories is now in its own bull market. It is outperforming and likely to outperform the Nifty.
May 29, 2012 at 11:27 | Source: MoneyControl.com
BANGALORE -(Dow Jones)- Ranbaxy Laboratories Ltd. (500359.BY) said Monday Canadian partner Cipher Pharmaceuticals Ltd. (DND.T) has received U.S. regulatory approval to make and sell a patented formulation of the acne medication Absorica.
May 29, 2012 at 10:58 | Source: NASDAQ
PRINCETON, N.J., May 29, 2012 /PRNewswire/ -- Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica™, a ...
May 29, 2012 at 14:04 | Source: Yahoo Finance
New Delhi: Drug firm Ranbaxy Laboratories on Monday said it has received approval from the US health regulator to launch Absorica, a patented acne treatment drug developed by Canadian firm Cipher Pharmaceuticals Inc, in the American market.
May 28, 2012 at 21:36 | Source: zeenews.india.com
Tokyo, May 25 (PTI) Drug major Ranbaxy Laboratories today said it has hired two US-based consultants to advise it on remedial work to be done at its manufacturing units in India as part of a consent decree signed with the USFDA to revoke ban imposed by the ...
May 25, 2012 at 09:30 | Source: MSN India
Ranbaxy Laboratories received FDA approval to market Cipher Pharmaceuticals' acne treatment Absorica. "Absorica is a critical milestone in our commitment to serve the dermatology community and will be the flagship brand for Ranbaxy's specialized ...
May 29, 2012 at 14:33 | Source: SmartBrief
May 9 (Reuters) - Ranbaxy Laboratories, India's top drugmaker by sales, reported a four-fold rise in quarterly net profit, helped by sales of its generic version of cholesterol drug Lipitor in its key U.S. market, sending its shares up more than ...
May 9, 2012 at 09:49 | Source: Reuters
According to a report from the "Economic Times of India", Teva has instead decided that it will help Indian companies Ranbaxy Laboratories and Dr. Reddy's Laboratories capture a larger market share of the drug in the US. Teva Americas CEO William Marth ...
May 29, 2012 at 06:26 | Source: Globes - Israel Business Arena